Addex Therapeutics Ltd ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$0.13next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 8 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly1.6MTarget: Sufficient funding to initiate IND-enabling studies for unpartnered programs
Neurosterix Equity Valuation Quarterly20.0Target: 20% equity interest appreciation driven by NTX-253 clinical milestones
Watch Items
- Neurosterix Phase 1 clinical trial readout for NTX-253 in schizophreniaTrigger: Completion of Phase 1 study in Q2 2026Action: Evaluate clinical data package (safety, tolerability, PK/PD) to de-risk the 20% equity stake
- Funding for independent GABAB PAM program in chronic coughTrigger: Securing financial backing or strategic partnershipAction: Initiate IND-enabling studies for the chronic cough candidate
- Nasdaq Minimum Bid Price ComplianceTrigger: ADS closing bid price below USD 1.00Action: Monitor bid price and evaluate options (e.g., reverse share split) to regain compliance
Research as of 20 Jun 2026